Cirius Therapeutics Stock

ciriustx.comHealthcareFounded: 2015Funding to Date: $68.9MM

Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's insulin sensitizer is used to treat nonalcoholic steatohepatitis which is characterized by buildup of fat and inflammation in the liver, may be accompanied by fibrosis and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients of liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.

Register for Details

For more details on financing and valuation for Cirius Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Cirius Therapeutics.

Register Today

Team

Management Team

Robert Baltera Jr.
Chief Executive Officer, President and Board Member
Howard Dittrich MD
Chief Medical Officer
Brian Farmer
Chief Financial Officer and Chief Business Officer
Jerry Colca Ph.D
Chief Scientific Officer

Board Members

David Van Andel
Nilesh Kumar Ph.D
Novo Holdings
Dennis Fenton Ph.D
Elaine Sun
Robert Zerbe
Daniel Estes Ph.D
Frazier Healthcare Partners
Michael Jandernoa
Robert Baltera Jr.

Other companies like Cirius Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM

News

Cirius Therapeutics didn't wait for the government shutdown to end before it filed its IPO in January. It was, as JP Morgan analysts had predicted the month prior,